Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists

Kidney International

Volumn 57, Issue 5, 2000, Pages 1803-1817

  Taal, Maarten W ^a   Brenner, Barry M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin II receptor antagonists; Blood pressure; Proteinuria; Renin angiotensin system; Renoprotection

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; KIDNEY FUNCTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0034118392     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00031.x     Document Type: Article

References (207)

1. 1. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
2. 2. RAVID M, SAVIN H, JUTRIN I, BENTAL T, KATZ B, LISHNER M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
3. 3. MASCHIO G, ALBERTI D, JANIN G, LOCATELLI F, MANN JF, MOTOLESE M, PONTICELLI C, RITZ E, ZUCHELLI P: Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
4. 4. GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA (GISEN): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
5. 5. RUGGENENTI P, PERNA A, GHERARDI G, GASPARI F, BENINI R, REMUZZI G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial: Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN): Ramipril Efficacy in Nephropathy. Lancet 352: 1252-1256, 1998
6. 6. HOSTETTER TH, OLSON JL, RENNKE HG, VENKATACHALAM MA, BRENNER BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981
7. 7. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
8. 8. ANDERSON S, MEYER TW, RENNKE HG, BRENNER BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612-619, 1985
9. 9. ANDERSON S, RENNKE HG, BRENNER BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
10. 10. BLANTZ RC, KONNEN KS, TUCKER BJ: Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 57:419-434, 1976
11. 11. ICHIKAWA I, MIELE JF, BRENNER BM: Reversal of renal cortical actions of angiotensin II by verapamil and manganese. Kidney Int 16:137-147, 1979
12. 12. MYERS B, DEEN WM, BRENNER BM: Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 37:101-110, 1975
13. 13. MILLER PL, RENNKE H, MEYER TW: Glomerular hypertrophy accelerates hypertensive glomerular injury in rats. Am J Physiol 261:F459-F465, 1991
14. 14. ZATZ R, DUNN BR, MEYER TW, ANDERSON S, RENNKE HG, BRENNER BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
15. 15. WESTENEND PJ, NOOYEN YA, VAN DER KROGT JA, VAN BRUMMELEN P, WEENING JJ: The effect of a converting enzyme inhibitor upon renal damage in spontaneously hypertensive Fawn Hooded rats. J Hypertens 10:417-422, 1992
16. 16. SAKEMI T, BABA N, YOSHIKAWA Y: Angiotensin-converting enzyme inhibition attenuates hypercholesterolemia and glomerular injury in hyperlipidemic Imai rats. Nephron 62:315-321, 1992
17. 17. MOULDER JE, FISH BL, COHEN EP: Treatment of radiation nephropathy with ACE inhibitors. Int J Radiat Oncol Biol Phys 27:93-99, 1993
18. 18. ANDERSON S, RENNKE HG, ZATZ R: Glomerular adaptations with normal aging and with long-term converting enzyme inhibition in rats. Am J Physiol 267:F35-F43, 1994
19. 19. LAPINSKI R, PERICO N, REMUZZI A, SANGALLI F, BENIGNI A, REMUZZI G: Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 7:653-660, 1996
20. 20. KAGAMI S, BORDER WA, MILLER DE, NOBLE NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
21. 21. RAY PE, BRUGGEMAN LA, HORIKOSHI S, AGUILERA G, KLOTMAN PE: Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 45:177-184, 1994
22. 22. WOLF G, HABERSTROH U, NEILSON EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140:95-107, 1992
23. 23. ARAI M, WADA A, ISAKA Y, AKAGI Y, SUGIURA T, MIYAZAKI M, MORIYAMA T, KANEDA Y, NARUSE K, NARUSE M, ORITA Y, ANDO A, KAMADA T, UEDA N, IMAI E: In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Commun 206:525-532, 1995
24. 24. FEENER EP, NORTHRUP JM, AIELLO LP, KING GL: Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 95:1353-1362, 1995
25. 25. VAN LEEUWEN RT, KOL A, ANDREOTTI F, KLUFT C, MASERI A, SPERTI G: Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 90:362-368, 1994
26. 26. VAUGHAN DE, LAZOS SA, TONG K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95:995-1001, 1995
27. 27. BARICOS WH, CORTEZ SL, EL-DAHR SS, SCHNAPER HW: ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47:1039-1047, 1995
28. 28. HAHN AW, JONAS U, BUHLER FR, RESINK TJ: Activation of human peripheral monocytes by angiotensin II. FEBS Lett 347:178-180, 1994
29. 29. FORIS G, DEZSO B, MEDGYESI GA, FUST G: Effect of angiotensin II on macrophage functions. Immunology 48:529-535, 1983
30. 30. KEANE WF, RAIJ L: Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. Lab Invest 52:599-604, 1985
31. 31. WEINSTOCK JV, KASSAB JT: Angiotensin II stimulation of granuloma macrophage phagocytosis and actin polymerization in murine schistosomiasis mansoni. Cell Immunol 89:46-54, 1984
32. 32. GREENE EL, KREN S, HOSTETTER TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98:1063-1068, 1996
33. 43. NAVAR LG, IMIG JD, ZOU L, WANG CT: Intrarenal production of angiotensin II. Semin Nephrol 17:412-422, 1997
34. 34. GUAN S, FOX J, MITCHELL KD, NAVAR LG: Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats. Hypertension 20:763-767, 1992
35. 35. VON THUN AM, VARI RC, EL-DAHR SS, NAVAR LG: Augmentation of intrarenal angiotensin II levels by chronic angiotensin II infusion. Am J Physiol 266:F120-F128, 1994
36. 36. MITCHELL KD, JACINTO SM, MULLINS JJ: Proximal tubular fluid, kidney, and plasma levels of angiotensin II in hypertensive ren-2 transgenic rats. Am J Physiol 273:F246-F253, 1997
37. 37. THE MICROALBUMINURIA CAPTOPRIL STUDY GROUP: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39:587-593, 1996
38. 38. SANO T, KAWAMURA T, MATSUMAE H, SASAKI H, NAKAYAMA M, HARA T, MATSUO S, HOTTA N, SAKAMOTO N: Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 17:420-424, 1994
39. 39. TREVISAN R, TIENGO A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients: North-East Italy Microalbuminuria Study Group. Am J Hypertens 8:876-883, 1995
40. 40. SANO T, HOTTA N, KAWAMURA T, MATSUMAE H, CHAYA S, SASAKI H, NAKAYAMA M, HARA T, MATSUO S, SAKAMOTO N: Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: Results of a 4-year, prospective, randomized study. Diabet Med 13:120-124, 1996
41. 41. AGARDH CD, GARCIA-PUIG J, CHARBONNEL B, ANGELKORT B, BARNETT AH: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 10:185-192, 1996
42. 42. AHMAD J, SIDDIQUI MA, AHMAD H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20:1576-1581, 1997
43. 43. THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000
44. 44. LEBOVITZ HE, WIEGMANN TB, CNAAN A, SHAHINFAR S, SICA DA, BROADSTONE V, SCHWARTZ SL, MENGEL MC, SEGAL R, VERSAGGI JA, BOLTON WK: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 45(Suppl 45):S150-S155, 1994
45. 45. YOKOYAMA H, TOMONAGA O, HIRAYAMA M, ISHII A, TAKEDA M, BABAZONO T, UJIHARA U, TAKAHASHI C, OMORI Y: Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 40:405-411, 1997
46. 46. NIELSEN FS, ROSSING P, GALL MA, SKOTT P, SMIDT UM, PARVING HH: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:1182-1188, 1997
47. 47. RUGGENENTI P, PERNA A, BENINI R, BERTANI T, ZOCCALI C, MAGGIORE Q, SALVADORI M, REMUZZI G: In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. Investigators of the GISEN Group: Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 10:997-1006, 1999
48. 48. RUGGENENTI P, PERNA A, GHERARDI G, GARINI G, ZOCCALI C, SALVADORI M, SCOLARI F, SCHENA FP, REMUZZI G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
49. 49. CAMPBELL DJ, KLADIS A, DUNCAN A-M: Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23:439-449, 1994
50. 50. CAMPBELL DJ, KLADIS A, VALENTIJN AJ: Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26:233-240, 1995
51. 51. BIOLLAZ J, BRUNNER HR, GAVRAS I, WAEBER B, GAVRAS H: Anti-hypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4:966-972, 1982
52. 52. ARAKAWA K: Serine protease angiotensin II systems. J Hypertens 14(Suppl 5):S3-S7, 1996
53. 53. MENTO PF, WILKES BM: Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 9:III42-III48, 1987
54. 54. NISHIMURA H, HOFFMANN S, BALTATU O, SUGIMURA K, GANTEN D, URATA H: Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Int 49(Suppl 55):S18-S23, 1996
55. 55. URATA H, BOEHM KD, PHILIP A, KINOSHITA A, GABROVSEK J, BUMPUS FM, HUSAIN A: Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 91:1269-1281, 1993
56. 56. URATA H, STROBEL F, GANTEN D: Widespread tissue distribution of human chymase. J Hypertension 12(Suppl 9):S17-S22, 1994
57. 57. CLARK KL, ROBERTSON MJ, DREW GM: Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog. Br J Pharmacol 109:148-156, 1993
58. 58. ARDAILLOU R: Angiotensin II receptors. J Am Soc Nephrol 10(Suppl 11):S30-S39, 1999
59. 59. CHUNG O, KUHL H, STOLL M, UNGER T: Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int 54(Suppl 67):S95-S99, 1998
60. 60. SHANMUGAM S, LLORENS-CORTES C, CLAUSER E, CORVOL P, GASC JM: Expression of angiotensin II AT2 receptor mRNA during development of rat kidney and adrenal gland. Am J Physiol 268:F922-F930, 1995
61. 61. NISHIMURA H, YERKES E, HOHENFELLNER K, MIYAZAKI Y, MA J, HUNLEY TE, YOSHIDA H, ICHIKI T, THREADGILL D, PHILLIPS JA III, HOGAN BM, FOGO A, BROCK JW III, INAGAMI T, ICHIKAWA I: Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell 3:1-10, 1999
62. 62. SIRAGY HM, CAREY RM: The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100:264-269, 1997
63. 63. SIRAGY HM, CAREY RM: The subtype 2 angiotensin receptor regulates renal prostaglandin F2 alpha formation in conscious rats. Am J Physiol 273:R1103-R1107, 1997
64. 64. TSUZUKI S, MATOBA T, EGUCHI S, INAGAMI T: Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension 28:916-918, 1996
65. 65. NAKAJIMA M, HUTCHISON HG, FUJINAGA M, HAYASHIDA W, MORISHITA R, ZIIANG L, HORIUCHI M, PRATT RE, DZAU V: The angiotensin II type 2 receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci USA 92:10663-10667, 1995
66. 66. MA J, NISHIMURA H, FOGO A, KON V, INAGAMI T, ICHIKAWA I: Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53:937-944, 1998
67. 67. MORRISSEY JJ, KLAHR S: Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol 276:F39-F45, 1999
68. 68. ICHIKI T, LABOSKY PA, SHIOTA C, OKUYAMA S, IMAGAWA Y, FOGO A, NIIMURA F, ICHIKAWA I, HOGAN BLM, INAGAMI T: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377:748-750, 1995
69. 69. ARIMA S, ENDO Y, YAOITA H, OMATA K, OGAWA S, TSUNODA K, ABE M, TAKEUCHI K, ABE K, ITO S: Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 100:2816-2823, 1997
70. 70. LIU Y-H, YANG X-P, SHAROV VG, NASS O, SABBAH HN, PETERSON E, CARRETERO OA: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest 99:1926-1935, 1997
71. 71. CERVENKA L, HELLER J, JELINEK F: Lack of a beneficial effect of PD123319, an AT2-angiotensin receptor antagonist, on the course of ablation nephropathy in the rat. Kidney Blood Press Res 19:241-244, 1996
72. 72. BROWN NJ, AGIRBASLI M, VAUGHAN DE: Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 34:285-290, 1999
73. 73. PETERS H, BORDFR WA, NOBLE NA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1570-1580, 1998
74. 74. MOMBOULI J-V, VANHOUTTE PM: Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: Role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol 20(Suppl 9):S74-S83, 1992
75. 75. FARHY RD, CARRETERO OA, HO K-L, SCICLI AG: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on ncointima formation. Circ Res 72:1202-1210, 1993
76. 76. BENETOS A, GAVRAS H, STEWART JM, VAVREK RJ, HATINOGLOU S, GAVRAS I: Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension 8:971-974, 1986
77. 77. CARBONELL LF, CARRETERO OA, STEWART JM, SCICLI AG: Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 11:239-243, 1988
78. 78. GAINER JV, MORROW JD, LOVELAND A, KING DJ, BROWN NJ: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensivc and hypertensive subjects. N Engl J Med 339:1285-1292, 1998
79. 79. SEINO M, ABE K, NUSHIRO N, OMATA K, KASAI Y, YOSHINAGA K: Effects of a competitive antagonist of bradykinin on blood pressure and renal blood flow in anesthetized rats. J Hypertens 6:867-871, 1988
80. 80. HAJJ-ALI AF, ZIMMERMAN BG: Kinin contribution to renal vasodilator effect of captopril in rabbit. Hypertension 17:504-509, 1991
81. 81. NAKAGAWA M, STEWART JM, VAVREK RJ, NASJLETTI A: Effects of a kinin antagonist on renal function in rats. Am J Physiol 258:F643-F648, 1990
82. 82. SEINO M, ABE K, NUSHIRO N, OMATA K, KASAI Y, YOSHINAGA K: Contribution of bradykinin to maintenance of blood pressure and renal blood flow in anaesthetized spontaneously hypertensive rats. J Hypertens 6(Suppl 4):S401-S403, 1988
83. 83. ZIMMERMAN BG, RAICH PC, VAVREK RJ, STEWART JM: Bradykinin contribution to renal blood flow effect of angiotensin converting enzyme inhibitor in the conscious sodium-restricted dog. Circ Res 66:234-240, 1990
84. 84. KON V, FOGO A, ICHIKAWA I: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 44:545-550, 1993
85. 85. DEMEILLIERS B, JOVER B, MIMRAN A: Contrasting renal effects of chronic administrations of enalapril and losartan on one-kidney, one clip hypertensive rats. J Hypertens 16:1023-1029, 1998
86. 86. HUTCHISON FN, CUI X, WEBSTER SK: The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 6:1216-1222, 1995
87. 87. TANAKA R, KON V, YOSHIOKA T, ICHIKAWA I, FOGO A: Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 45:537-543, 1994
88. 88. BROWN NJ, NADEAU JH, VAUGHAN DE: Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 77:522-525, 1997
89. 89. SMITH D, GILBERT M, OWEN WG: Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66:835-839, 1985
90. 90. ISHIDOYA S, MORRISSEY J, MCCRACKEN R, REYES A, KLAHR S: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47:1285-1294, 1995
91. 91. KOHZUKI M, KANAZAWA M, LIU PF, KAMIMOTO M, YOSHIDA K, SAITO T, YASUJIMA M, SATO T, ABE K: Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: Chronic effects on cardio-and renoprotection of angiotensin converting enzyme inhibitors. J Hypertens 13:1785-1790, 1995
92. 92. NABOKOV A, AMANN K, GASSMANN P, SCHWARZ U, ORTH SR, RITZ E: The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 13:173-176, 1998
93. 93. ALLEN TJ, CAO Z, YOUSSEF S, HULTHEN UL, COOPER ME: Role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies. Diabetes 46:1612-1618, 1997
94. 94. ISRAILI ZH, HALL WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 117:234-242, 1992
95. 95. LAFAYETTE RA, MAYER G, PARK SK, MEYER TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90:766-771, 1992
96. 96. POLLOCK DM, DIVISH BJ, POLAKOWSKI JS, OPGENORTH TJ: Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 267:657-663, 1993
97. 97. BROOKS DP, CONTINO LC, SHORT BG, GOWAN C, TRIZNA W, EDWARDS RM: SB 203220: A novel angiotensin II receptor antagonist and renoprotective agent. J Pharmacol Exp Ther 274:1222-1227, 1995
98. 98. OKADA H, SUZUKI H, KANNO Y, IKENAGA H, SARUTA T: Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovasc Pharmacol 26:564-569, 1995
99. 99. OTS M, MACKENZIE HS, TROY JL, RENNKE HG, BRENNER BM: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 9:224-230, 1998
100. 100. HAMAGUCHI A, KIM S, WANIBUCHI H, IWAO H: Angiotensin II and calcium blockers prevent glomerular phenotypic changes in remnant kidney model. J Am Soc Nephrol 7:687-693, 1996
101. 101. MACKENZIE HS, TROY JL, RENNKE HG, BRENNER BM: TCV116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertension 12(Suppl 9):S11-S16, 1994
102. 102. YAMAMOTO M, FUKUI M, SHOU I, WANG LN, SEKIZUKA K, SUZUKI S, SHIRATO I, TOMINO Y: Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (Ang IIRA) on renal function and glomerular injury in subtotal nephrectomized rats. J Clin Lab Anal 11:53-62, 1997
103. 103. KAKINUMA Y, KAWAMURA T, BILLS T, YOSHIOKA T, ICHIKAWA I, FOGO A: Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1992
104. 104. WU LL, COX A, ROE CJ, DZIADEK M, COOPER ME, GILBERT RE: Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 51:1553-1567, 1997
105. 105. JUNAID A, ROSENBERG ME, HOSTETTER TH: Interaction of angiotensin II and TGF-beta 1 in the rat remnant kidney. J Am Soc Nephrol 8:1712-1738, 1997
106. 106. WU LL, YANG N, ROE CJ, COOPER ME, GILBERT RE, ATKINS RC, LAN HY: Macrophage and myofibroblast proliferation in remnant kidney: Role of angiotensin II. Kidney Int 52(Suppl 63):S221-S225, 1997
107. 107. LAREVIERE R, LEBEL M, KINGMA I, GROSE JH, BOUCHER D: Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am J Hypertens 11:989-997, 1998
108. 108. NODA M, MATSUO T, FUKUDA R, OHTA M, NAGANO H, SHIBOUTA Y, NAKA T, NISHIKAWA K, IMURA Y: Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int 56:898-909, 1999
109. 109. TAAL MW, BRENNER BM: ACE-I vs. angiotensin II receptor antagonists: Prevention of renal injury in chronic rat models. J Hum Hypenens 13(Suppl 1):S51-S56, 1999
110. 110. REMUZZI A, PERICO N, AMUCHASTEGUI CS, MALANCHINI B, MAZERSKA M, BATTAGLIA C, BERTANI T, REMUZZI G: Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4:40-49, 1993
111. 111. KIM S, WANIBUCHI H, HAMAGUCHI A, MIURA K, YAMANAKA S, IWAO H: Angiotensin blockade improves cardiac and renal complications of type II diabetic rats. Hypertension 30:1054-1061, 1997
112. 112. KOHZUKI M, YASUJIMA M, KANAZAWA M, YOSHIDA K, PING FU L, OBARA K, SAITO T, ABE K: Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertension 13:97-103, 1995
113. 113. KATO S, LUYCKX VA, OTS M, LEE KW, ZIAI F, TROY JL, BRENNER BM, MACKENZIE HS: Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 56:1037-1048, 1999
114. 114. ZIAI F, OTS M, PROVOOST AP, TROY JL, RENNKE HG, BRENNER BM, MACKENZIE HS: The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int 50(Suppl 57):S132-S136, 1996
115. 115. IMAMURA A, MACKENZIE HS, LACY ER, HUTCHISON FN, PLOTH DW: Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. Kidney Int 47:1394-1402, 1995
116. 116. GEIGER H, FIERLBECK W, MAI M, RUCHTI H, SCHONFELD V, DAMMRICH J, HUGO C, NEUMAYER HH: Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. Kidney Int 51:750-761, 1997
117. 117. INADA Y, WADA T, OJIMA M, SANADA T, SHIBOUTA Y, KANAGAWA R, ISHIMURA Y, FUJISAWA Y, NISHIKAWA K: Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 19:1079-1099, 1997
118. 118. WAGNER J, DRAB M, BOHLENDFR J, AMANN K, WIENEN W, GANTEN D: Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 20:205-221, 1998
119. 119. WEBB RL, BARCLAY BW, NAVARRETE AE, WOSU NJ, SAHOTA P: Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 20:775-793, 1998
120. 120. KIM S, OHTA K, HAMAGUCHI A, OMURA T, YUKIMURA T, MIURA K, INADA Y, WADA T, ISHIMURA Y, CHATANI F, IWAO H: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24:195-204, 1994
121. 121. OBATA J, NAKAMURA T, KUROYANAGI R, YOSHIDA Y, GUO DF, INAGAMI T: Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int 52(Suppl 63):S229-S231, 1997
122. 122. CASELLAS D, BENAHMED S, ARTUSO A, JOVER B: Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats. J Am Soc Nephrol 10(Suppl 11): S230-S233, 1999
123. 123. CAMARGO MJ, VON LUTTEROTTI N, CAMPBELL WG JR, PECKER MS, JAMES GD, TIMMERMANS PB, LARAGH JH: Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 11:31-40, 1993
124. 124. AMUCHASTEGUI SC, AZZOLLINI N, MISTER M, PEZZOTTA A, PERICO N, REMUZZI G: Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 9:1948-1955, 1998
125. 125. BENEDIKTSSON H, CHEA R, DAVIDOFF A, PAUL LC: Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Transplantation 62:1634-1642, 1996
126. 126. MACKENZIE HS, ZIAI F, NAGANO H, AZUMA H, TROY JL, RENNKE HG, TILNEY NL, BRENNER BM: Candesartan cilexetil reduces chronic renal allograft injury in Fisher→Lewis rats. J Hypertens 15(Suppl 6):S21-S25, 1997
127. 127. MACKENZIE HS, ZIAI F, OMER SA, NADIM M, TAAL MW: Angiotensin receptor blockers in chronic renal disease: The promise of a bright clinical future. J Am Soc Nephrol 10(Suppl 12):S283-S286, 1999
128. 128. ZOJA C, DONADELLI R, CORNA D, TESTA D, FACCHINETTI D, MAFFI R, LUZZANA E, COLOSIO V, BERTANI T, REMUZZI G: The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis 29:254-264, 1997
129. 129. NAKAMURA T, OBATA J, ONIZUKA M, KIMURA H,OHNO S, YOSHIDA Y, KAWACHI H, SHIMIZU F: Candesartan prevents the progression of mesangioproliferative nephritis in rats. Kidney Int 52(Suppl 63):S226-S228, 1997
130. 130. ZOJA C, ABBATE M, CORNA D, CAPITANIO M, DONADELLI R, BRUZZI I, OLDROYD S, BENIGNI A, REMUZZI G: Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis 31:453-463, 1998
131. 131. REMUZZI A, MALANCHINI B, BATTAGLIA C, BERTANI T, REMUZZI G: Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp Nephrol 4:19-25, 1996
132. 132. SAKEMI T, BABA N: Effects of angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. Nephron 65:426-432, 1993
133. 133. SHIHAB FS, BENNETT WM, TANNER AM, ANDOH TF: Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 52:660-673, 1997
134. 134. RICHER C, BRUNEVAL P, MENARD J, GIUDICELLI JF: Additive effects of enalapril and losartan in (mREN-2) 27 transgenic rats. Hypertension 31:692-698, 1998
135. 135. MOGENSEN CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 36:383-388, 1976
136. 136. PARVING HH, ANDERSEN AR, SMIDT UM, SVENDSEN PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175-1179, 1983
137. 137. KASISKE BL, KALIL RS, MA JZ, LIAO M, KEANE WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138, 1993
138. 138. KLAG MJ, WHELTON PK, RANDALL BL, NEATON JD, BRANCATI FL, FORD CE, SHULMAN NB, STAMLER J: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
139. 139. PETERSON JC, ADLER S, BURKART JM, GREENE T, HEBERT LA, HUNSICKER LG, KING AJ, KLAHR S, MASSRY SG, SEIFTER JL: Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
140. 140. BIDANI AK, GRIFFIN KA, PICKEN M, LANSKY DM: Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am J Physiol 265:F391-F398, 1993
141. 141. SIMONS JL, PROVOOST AP, DE KEIJZER MH, ANDERSON S, RENNKE HG, BRENNER BM: Pathogenesis of glomerular injury in the Fawn-Hooded rat: Effect of unilateral nephrectomy. J Am Soc Nephrol 4:1362-1370, 1993
142. 142. BURNIER M, RUTSCHMANN B, NUSSBERGER J, VERSAGGI J, SlIAHINFAR S, WAEBER B, BRUNNER HR: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22:339-347, 1993
143. 143. BURNIER M, HAGMAN M, NUSSBERGER J, BIOLLAZ J, ARMAGNAC C, BROUARD R, WEBER B, BRUNNER HR: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 25:602-609, 1995
144. 144. GILLIS JC, MARKHAM A: Irbesartan: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 54:885-902, 1997
145. 145. JOHNSTON CI: Angiotensin receptor antagonists: Focus on losartan. Lancet 346:1403-1407, 1995
146. 146. MARKHAM A, GOA KL: Valsartan: A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54:299-311, 1997
147. 147. MCCLELLAN KJ, MAKKHAM A: Telmisartan. Drugs 56:1039-1044, 1998
148. 148. MCCLELLAN KJ, BALFOUR JA: Eprosartan. Drugs 55:713-718, 1998
149. 149. MCINTYRE M, CAFFE SE, MICHALAK RA, REID JL: Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension. Pharmacol Ther 74:181-194, 1997
150. 150. REEVES RA, LIN CS, KASSLER-TAUB K, POULEUR H: Dose-related efficacy of irbesartan for hypertension: An integrated analysis. Hypertension 31:1311-1316, 1998
151. 151. SEVER P: Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens 11(Suppl 2):S91-S95, 1997
152. 152. DAHLOF B, KELLER SE, MAKRIS L, GOLDBERG AI, SWEET CS, LIM NY: Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 8:578-583, 1995
153. 153. CIFKOVA R, PELESKA J, HRADEC J, ROSOLOVA H, PINTEROVA E, ZEMAN K, ODDOU-STOCK P, THIRLWELL J, BOTTERI F: Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 12:563-567, 1998
154. 154. MACKAY JH, ARCURI KE, GOLDBERG AI, SNAPINN SM, SWEET CS: Losartan and low-dose hydrochlorothiazide in patients with essential hypertension: A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 156:278-285, 1996
155. 155. COREA L, CARDONI O, FOGARI R, INNOCENTI P, PORCELLATI C, PROVVIDENZA M, MEILENBROCK S, SULLIVAN J, BODIN F: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 60:341-346, 1996
156. 156. BLACK HR, GRAFF A, SHUTE D, STOLTZ R, RUFF D, LEVINE J, SHI Y, MALLOWS S: Valsartan, a new angiotensin II antagonist for the treatment, of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 11:483-489, 1997
157. 157. GRADMAN AH, ARCURI KE, GOLDBERG AI, IKEDA LS, NELSON EB, SNAVELY DB, SWEET CS: A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 25:1345-1350, 1995
158. 158. HOLWERDA NJ, FOGARI R, ANGELI P, PORCELLATI C, HERENG C, ODDOU-STOCK P, HEATH R, BODIN F: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril. J Hypertens 14:1147-1151, 1996
159. 159. MIMRAN A, RUILOPE L, KERWIN L, NYS M, OWENS D, KASSLER-TAUB K, OSBAKKEN M: A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 12:203-208, 1998
160. 160. TIKKANEN I, OMVIK P, JENSEN HA: Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 13:1343-1351, 1995
161. 161. FRIDMAN K, ANDERSSON OK, WYSOCKI M, FRIBERG P, SUNZEL M: Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol 54:497-501, 1998
162. 162. PECHERE-BERTSCHI A, NUSSBERGER J, DECOSTERD L, ARMAGNAC C, SISSMANN J, BOUROUDIAN M, BRUNNER HR, BURNIER M: Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 16: 385-393, 1998
163. 163. ERLEY CM, BADER B, SCHEU M, WOLF S, BRAUN N, RISLER T: Renal hemodynamics in essential hypertensives treated with losartan. Clin Nephrol 43(Suppl 1):S8-S11, 1995
164. 164. FAUVEL JP, VELON S, BERRA N, POZET N, MADONNA O, ZECH P, LAVILLE M: Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 28:259-263, 1996
165. 165. GANSEVOORT RT, DE ZEEUW D, DE JONG PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int 45:861-867, 1994
166. 166. TOTO R, SHULTZ P, RAIJ L, MITCHELL H, SHAW W, RAMJIT D, TOH J, SHAHINFAR S: Efficacy and tolerability of losartan in hypertensive patients with renal impairment: Collaborative Group. Hypertension 31:684-691, 1998
167. 167. BUTER H, NAVIS G, DE ZEEUW D, DE JONG PE: Renal hemodynamic effects of candesartan in normal and impaired renal function in humans. Kidney Int 52(Suppl 63):S185-S187, 1997
168. 168. PITT B, SEGAL R, MARTINEZ FA, MEURERS G, COWLEY AJ, THOMAS I, DEEDWANIA PC, NEY DE, SNAVELY DB, CHANG PI: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747-752, 1997
169. 169. WEBER M: Clinical safety and tolerabilily of losartan. Clin Ther 19:604-616, 1997
170. 170. DEL CASTILLO D, CAMPISTOL JM, GUIRADO L, CAPDEVILLA L, MARTINEZ JG, PEREIRA P, BRAVO J, PEREZ R: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 54(Suppl 68):S135-S139, 1998
171. 171. APPERLOO AJ, DE ZEEUW D, DE JUNG PE: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51:793-797, 1997
172. 172. MOGENSEN CE, CHRISTENSEN CK: Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89-93, 1984
173. 173. PARVING HH, OXENBOLL B, SVENDSEN PA, CHRISTIANSEN JS, ANDERSEN AR: Early detection of patients at risk of developing diabetic nephropathy: A longitudinal study of urinary albumin excretion. Acta Endocrinol 100:550-555, 1982
174. 174. YUDKIN JS, FORREST RD, JACKSON CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington Diabetes Survey. Lancet 2:530-533, 1988
175. 175. DAMSGAARD EM, FROLAND A, JORGENSEN OD, MOGENSEN CE: Microalbuminuria as predictor of increased mortality in elderly people. Br Med J 300:297-300, 1990
176. 176. HAFTNER SM, STERN MP, GRUBER MK, HAZUDA HP, MITCHELL BD, PATTERSON JK: Microalbuminuria: Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 10:727-731, 1990
177. 177. MAITOCK MB, MORRISH NJ, VIBERTI G, KEEN H, FITZGERALD AP, JACKSON G: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41:736-741, 1992
178. 178. ROVIN BH, TAN LC: LDL stimulates mesangial fibroneclin production and chemoattractant expression. Kidney Int 43:218-225, 1993
179. 179. GRONE EF, ABBOUD HE, HOHNE M, WALLI AK, GRONE HJ, STUKER D, ROBENEK H, WIELAND E, SEIDEL D: Actions of lipoproteins in cultured human mesangial cells: Modulation by mitogenic vasoconstrictors. Am J Physiol 263:F686-F696, 1992
180. 180. WANG Y, CHEN J, CHEN L, TAY YC, RANGAN GK, HARRIS DC: Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 8:1537-1545, 1997
181. 181. ABBATE M, ZOJA C, CORNA D, CAPITANIO M, BERTANI T, REMUZZI G: In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9:1213-1224, 1998
182. 182. BURTON C, HARRIS KP: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 27:765-775, 1996
183. 183. REMUZZI G, BERTANI T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
184. 184. NIELSEN S, DOLLERUP J, NIELSEN B, JENSEN HA, MOGENSEN CE: Losartan reduces albuminuria in patients with essential hypertension: An enalapril controlled 3 months study. Nephrol Dial Transplant 2:19-23, 1997
185. 185. CHAN JC, CRITCHLEY JA, TOMLINSON B, CHAN TY, COCKRAM CS: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 17:72-80, 1997
186. 186. PLUM J, BÜNTEN B, NÉMETH R, GRABENSEE B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 9:2223-2234, 1998
187. 187. FERNANDEZ-ANDRADE C, RUSSO D, IVERSEN B, ZUCCHELLI P, ARANDA P, GUERRA L, CASADO S: Comparison of losartan and amlodipinc in renally impaired hypertensive patients. Kidney Int 54(Suppl 68):S120-S124, 1998
188. 188. HOIDAAS H, HARTMANN A, BERG KJ, LUND K, FAUCHALD P: Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 13:3096-3102, 1998
189. 189. PERICO N, REMUZZI A, SANGALLI F, AZZOLLINI N, MISTER M, RUGGENENTI P, REMUZZI G: The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 9:2308-2317, 1998
190. 190. AZIZI M, CHATELLIER G, GUYENE TT, MURIFTA-GEOFFROY D, MENARD J: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92:825-834, 1995
191. 191. ZOCCALI C, VALVO E, RUSSO D, PANICHI V, ZUCCALA A: Antiproteinuric effect of Losartan in patients with chronic renal diseases. (letter) Nephrol Dial Transplant 12:234-235, 1997
192. 192. RUSSO D, PISANI A, BALLETTA MM, DE NICOLA L, SAVINO FA, ANDREUCCI M, MINUTOLO R: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856, 1999
193. 193. MIMRAN A, RIBSTEIN J: Angiotensin receptor blockers: Pharmacology and clinical significance. J Am Soc Nephrol 10(Suppl 12): S273-S277, 1999
194. 194. ANDERSSON OK, NELDAM S: A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 11:S63-S64, 1997
195. 195. KASSLER-TAUB K, LITTLEJOHN T, ELLIOTT W, RUDDY T, ADLER E: Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension: Irbesartan/Losartan Study Investigators. Am J Hypertens 11:445-453, 1998
196. 196. OPARIL S, GUTHRIE R, LEWIN AJ, MARBURY T, REILLY K, TRISCARI J, WITCHER JA: An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan: Irbesartan/Losartan Sludy Investigators. Clin Ther 20:398-409, 1998
197. 197. GANSEVOORT RT, DE ZEEUW D, SHAHINTAR S, REDFIELD A, DE JONG PE: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 12(Suppl 2):S37-S42, 1994
198. 198. SOFFER BA, WRIGHT JT JR, PRATI JH, WIENS B, GOLDBERG AI, SWEET CS: Effects of losarlan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 26:112-117, 1995
199. 199. MINGHELLI G, SEYDOUX C, GOY JJ, BURNIER M: Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 66:268-271, 1998
200. 200. BURNIER M, ROCH-RAMEL F, BRUNNER HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 49:1787-1790, 1996
201. 201. EDWARDS RM, TRIZNA W, STACK EJ, WEINSTOCK J: Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 276:125-129, 1996
202. 202. FREEDMAN DS, WILLIAMSON DF, GUNTER EW, BYERS T: Relation of serum uric acid to mortality and ischemic heart disease: The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141:637-644, 1995
203. 203. WARD HJ: Uric acid as an independent risk factor in the treatment of hypertension. Lancet 352:670-671, 1998
204. 204. GOLDBERG AI, DUNLAY MC, SWEET CS: Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 75:793-795, 1995
205. 205. BENZ J, OSHRAIN C, HENRY D, AVERY C, CHIANG YT, GATLIN M: Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 37:101-107, 1997
206. 206. LACOURCIERE Y, BRUNNER H, IRWIN R, KARLBERG BE, RAMSAY LE, SNAVELY DB, DOBBINS TW, FAISON EP, NELSON EB: Effects of modulators of the renin-angiotensin-aldosterone system on cough: Losartan Cough Study Group. J Hypertens 12:1387-1393, 1994
207. 207. SHARMA PK, YIUM JJ: Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 90:552-553, 1997